NGNE at a glance
Neurogene Inc. (NGNE, SEC CIK 1404644) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Neurogene Inc. (NGNE) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $90.4 million. Diluted EPS was -$4.24.
- As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Neurogene Inc. (NGNE) shares worth $122.9 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Cvijic Christine Mikail on July 7, 2026 of 4,200 shares at $36.13 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- −100.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 21 funds
- $122.9M · −3 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- No product revenue, unchanged from prior-year quarter; net loss $29.0M vs $21.0M YoY
- Operating margin not applicable, operating loss $32.4M vs $23.8M YoY
- Rett syndrome program largest expense, $8.9M vs $5.6M YoY
- Cash, equivalents and short-term investments $359.7M; operating cash use $79.0M nine-month period
- July offering raised $134.9M; runway extended into first quarter of 2029, topline NGN-401 data expected second half 2027
Risk Factors
- Newly emphasized regulatory risk: FDA denied NGN-101’s RMAT designation, removing the streamlined registrational pathway and potentially ending further investment
- Most material clinical update: NGN-401’s 3E15 vg dose was removed after a November 2024 fatal SAE, with additional safety monitoring added
- Operational risk: NGN-401 remains dependent on successful Embolden trial execution after dosing completion in the second quarter of 2026
- Financial risk: $447.1 million cumulative net loss, with existing cash expected to fund operations into the first quarter of 2029
- Supply-chain risk: U.S. tariffs and BIOSECURE Act restrictions could disrupt Chinese biotechnology relationships and increase material costs
AI summary of the NGNE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Updated corporate presentation highlights current corporate and investor messaging
Item EX-99.1: Item EX-99.1
- Embolden topline data expected 2H 2027, with 25 participants in primary efficacy analysis and a 9-of-25 success threshold
- NGN-401 1E15 vg dose generally well-tolerated across 35 participants as of November 8, 2026
Item EX-99.2: Item EX-99.2
- Embolden registrational trial fully dosed, N=25, exceeding target enrollment and supporting a potential broad age label for patients ≥3 years
- Topline Embolden data expected 2H 2027, the key clinical catalyst for NGN-401’s potential approval
Item EX-99.1: Item EX-99.1
- Phase 1/2 efficacy signal strengthened: 100% of participants improved on CGI-I and gained milestones, averaging 4.7 each through 30 months
- NGN-401 safety remained generally well-tolerated at 1E15 vg across 35 participants, supporting continued registrational development
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Updated corporate presentation provides investors with refreshed company and pipeline information
Item EX-99.2: Item EX-99.2
- Embolden registrational trial fully dosed with 25 participants, supporting a single-trial BLA strategy for females aged ≥3 years
- Phase 1/2 data: 100% of 10 participants gained milestones, 80% met the composite responder definition, with 4.7 average gains
Item 8.01: Other Events
- Offering proceeds extend Neurogene’s funding runway through the first quarter of 2029
- Combined liquidity expected to cover operating expenses and capital expenditures
Item 1.01: Entry into a Material Definitive Agreement
- $134.8M expected net proceeds from equity offering, strengthening Neurogene’s cash position
- 3.5M common shares sold at $30.00 plus pre-funded warrants for 666,666 shares
AI summaries of NGNE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NGNE
Don't miss the next NGNE filing
- Alerts as it files. A push when NGNE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NGNE, by share count.
- Ask anything. An AI agent that reads every NGNE filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| McMinn Rachel | M | Sep 22, 2026 | 756 | - |
| McMinn Rachel | M | Sep 22, 2026 | 756 | $25.32 |
| Cvijic Christine Mikail | Sell | Jul 7, 2026 | 4,200 | $36.13 |
| Cvijic Christine Mikail | Sell | Jul 6, 2026 | 600 | $36.02 |
| Cvijic Christine Mikail | Sell | Jul 2, 2026 | 1,530 | $35.23 |
| Cvijic Christine Mikail | Sell | Jul 2, 2026 | 2,531 | $34.58 |
| Cvijic Christine Mikail | Sell | Jul 2, 2026 | 1,530 | $35.23 |
| Cvijic Christine Mikail | Sell | Jul 2, 2026 | 2,531 | $34.58 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $925K | $0 |
| Operating Income | -$55.6M | -$82.6M | -$103.3M |
| Net Income | - | -$75.1M | -$90.4M |
| Op. Margin | - | -8930.3% | - |
| Net Margin | - | -8123.7% | - |
| Balance Sheet | |||
| Total Assets | - | $335.7M | $288.6M |
| Equity | - | $310.4M | $264.9M |
| ROE | - | -24.2% | -34.1% |
| Per Share | |||
| EPS | $2.93 | $-4.28 | $-4.24 |
| Cash Flow | |||
| Operating CF | -$51.4M | -$70.6M | -$77.2M |
| CapEx | $321K | $808K | $1.2M |
Source: XBRL data in Neurogene Inc. (NGNE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate NGNE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 21 | $122.9M |
| Q2 2026 | 24 | $109.5M |
| Q1 2026 | 21 | $71.6M |
| Q4 2025 | 20 | $67.1M |
| Q3 2025 | 16 | $49.0M |
| Q2 2025 | 17 | $50.7M |
| Q1 2025 | 16 | $25.1M |
| Q4 2024 | 12 | $43.3M |
- Franklin Resources+426.6K (+209%)
- BlackRock+414.0K (+39%)
- State Street Corp+324.9K (+145%)
- Vanguard Capital Management LLC+174.8K (+33%)
- Vanguard Portfolio Management LLC+78.7K (+82%)
- Citadel Advisors LLC−316.1K (-77%)
- Millennium Management−18.1K (-42%)
- Renaissance Technologies LLC−10.2K (-50%)
- Wells Fargo & Co−6.4K (-68%)
- PNC Financial Services−4.3K (-96%)
- FMR LLC (Fidelity)−295.6K
- D.E. Shaw & Co−9.8K
- Invesco Ltd−6.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 147 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NGNE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Oct 2, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 7, 2026 | - | - | |
| 8-K | Apr 20, 2026 | - | Analysis | - |
| 4 | Mar 30, 2026 | - | - | - |
| 4 | Mar 30, 2026 | - | - | - |
| 4 | Mar 30, 2026 | - | - | - |
| 10-K | Mar 24, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 24, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
NGNE SEC filings: frequently asked questions
Which institutions hold NGNE stock?
As of September 30, 2026, the largest Neurogene Inc. (NGNE) holders among the 13F filers tracked by SignalX were BlackRock ($41.0 million), Vanguard Capital Management LLC ($19.8 million), Franklin Resources ($17.4 million), State Street Corp ($15.3 million), Morgan Stanley ($6.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NGNE's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Neurogene Inc. (NGNE) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $90.4 million. Diluted EPS was -$4.24. The figures come from the XBRL data in the 10-K.
What did NGNE report in its latest 8-K?
Neurogene Inc. (NGNE) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest NGNE SEC filings?
Neurogene Inc. (NGNE) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on October 2, 2026.
What is NGNE's SEC CIK number?
Neurogene Inc. (NGNE)'s SEC Central Index Key (CIK) is 1404644. EDGAR lists every NGNE filing under that number.
Ask anything about NGNE
The research agent reads NGNE's filings, financials, insider trades and 13F holders, then answers with sources.